Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
4.200
-0.100 (-2.33%)
Aug 14, 2026, 12:47 PM EDT - Market open
Ernexa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
6.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
| Dec 31, 2023 | 68.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 24.06M | 194.00K | 0.81% |
| Dec 31, 2011 | 23.87M | -1.44M | -5.69% |
| Dec 31, 2010 | 25.31M | -505.00K | -1.96% |
| Dec 31, 2009 | 25.81M | -1.68M | -6.12% |
| Dec 31, 2008 | 27.50M | -3.05M | -9.97% |
| Dec 31, 2007 | 30.54M | -2.44M | -7.41% |
| Dec 31, 2006 | 32.99M | 2.24M | 7.27% |
| Dec 31, 2005 | 30.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioAtla | 2.00M |
| GeoVax Labs | 852.28K |
| BioRestorative Therapies | 357.87K |
| AIM ImmunoTech | 95.00K |
| Alaunos Therapeutics | 3.00K |
| Soligenix | 2.34K |
ERNA News
- 4 days ago - Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage - GlobeNewsWire
- 21 days ago - Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies - GlobeNewsWire
- 4 weeks ago - Ernexa Therapeutics announces new ERNA-101 preclinical data - TheFly
- 4 weeks ago - Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry - GlobeNewsWire
- 4 weeks ago - Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer - GlobeNewsWire